SUNY, NYU, Galderma Sue Generics Firm Mylan for Allegedly Infringing Rosacea Rx IP | GenomeWeb

The State University of New York, dermatology company Galderma, and New York University last week sued generic drug manufacturer Mylan Pharmaceuticals for allegedly infringing four patents related to Oracea, Galderma's orally administered treatment for rosacea.

Although SUNY and NYU's financial stake in the proceedings is unclear, they are seeking to protect a royalty stream that dates back to a 1992 licensing agreement with Galderma predecessor Collagenix Pharmaceuticals for some of the patents protecting Oracea, which exceeded $50 million in sales in 2007.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.